Chlamydia Infection Diagnostics Market Size, Key Companies, Company Technology / Innovation, Production Economics, Trade Analysis, Material Efficiency, Market Penetration, Company Investment Strategies, and Sustainability Trends

Chlamydia Infection Diagnostics Market Growth, Demand, and Production Forecast 2035

The chlamydia infection diagnostics market is forecasted to expand from USD 874.26 million in 2026 to USD 1,580.46 million by 2035, growing at a CAGR of 6.80% from 2026 to 2035.

Key Takeaways

Market Size & Growth Outlook

• Market size in 2025: USD 818.60 million
• Estimated market size in 2026: USD 874.26 million
• Projected market size by 2035: USD 1,580.46 million
• CAGR (2026-2035): 6.80%

Regional Market Spotlight

• North America led the market with a 42.60% (USD 348.72 million) share in 2025.
• Europe accounted for 26.80% (USD 219.38 million) of the market in 2025.
• Asia Pacific accounted for 21.20% (USD 173.54 million) of the market in 2025 and is projected to be the fastest-growing region, at a CAGR of 8.13% from 2025 to 2035.

Segmental Spotlight

• By test type, NAAT accounted for 76.40% (USD 625.41 million) in 2025.
• By infection type, Genital accounted for 81.20% (USD 664.70 million) in 2025.
• By setting, Laboratory-based accounted for 74.60% (USD 610.68 million) in 2025.
• By end user, Diagnostic Laboratories accounted for 40.60% (USD 332.35 million) in 2025.

Chlamydia Infection Diagnostics Market Size and Forecast, 2025-2035 (USD Million)

Note: 2025 is the base year; 2026–2035 values are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

The chlamydia infection diagnostics market is projected to grow from USD 818.60 million in 2025 to USD 1,580.46 million by 2035 because screening programs test large numbers of young adults each year, and most testing uses high-value NAATs on urine and swab samples. Rapid point-of-care and at-home molecular tests add new testing channels outside laboratories, lifting the market to USD 1,137.44 million by 2030 and sustaining a CAGR of 6.80% from 2026 to 2035.

• Analyst View: We built the estimate from chlamydia test volumes by setting and region, based on screening rates in target age groups, symptomatic testing and partner testing, multiplied by average prices for laboratory NAAT, point-of-care, home, and other tests. Volumes reflect national screening guidelines, sexual health clinic activity and the use of combined chlamydia, gonorrhea and trichomoniasis panels. The total was cross-checked against the STI testing revenue of leading molecular diagnostics companies and against published estimates, which places our base year slightly above the comparable figures. The growth rate will be influenced by screening activities that have been consistent, as well as the change to rapid tests and at-home molecular testing.

Market Trends

• At-home molecular STI tests are now available without a prescription.
• Rapid point-of-care PCR allows test-and-treat in one visit.
• Extra-genital rectal and throat testing is increasing.
• Online self-sampling services are expanding in Europe.
• Multiplex panels combine chlamydia with other STIs.
• Automated lab systems screen through large volumes.

Drivers, Restraints and Opportunities

Driver

Chlamydia is one of the most common bacterial STIs, and most infections have no symptoms, so regular screening of young adults is recommended. NAATs allow accurate testing on easy-to-collect urine and self-collected swabs. Rapid point-of-care molecular tests allow clinics to diagnose and treat patients in a single visit. Home tests and self-sampling kits help reach those who do not go to clinics.

Restraint

High-volume laboratory NAATs face strong price pressure from payers and public health tenders. Infected individuals remain undetected due to the lack of symptoms. Point-of-care and home tests cost more than laboratory tests per result. Molecular tests are less accessible in poor countries due to the syndromic approach that is employed. Sexual health stigma limits testing.

Opportunity

Over-the-counter home molecular tests can reach young adults who do not visit clinics. Point-of-care testing in pharmacies and telehealth services can expand screening. Mycoplasma genitalium and markers for antibiotic resistance can enhance test value when combined in multiplex panels. Low-cost molecular tests can support STI programs in Asia, Africa, and Latin America. Integration with digital health apps can improve linkage to treatment.

Market Segmentation: 2025 Share and Value

Chlamydia Infection Diagnostics Market by Test Type 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

NAATs accounted for 76.40% (USD 625.41 million) in 2025 because guidelines recommend them as the test of choice and they detect chlamydia accurately in urine, vaginal, rectal, and throat samples. Laboratory-based high-throughput platforms have chlamydia-gonorrhea test panels, while portable point-of-care tests provide results within less than an hour. Serology and rapid tests, at 12.60% (USD 103.14 million), are used where molecular testing is not available and for some research and fertility work-ups, direct fluorescent antibody tests account for 6.20% (USD 50.75 million) and culture accounts for 4.80% (USD 39.29 million), mainly for medico-legal cases and antimicrobial studies.

Chlamydia Infection Diagnostics Market by Infection Type 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Genital infections accounted for 81.20% (USD 664.70 million) in 2025 because most screening uses urine or vaginal and cervical swabs from young women and men. Rectal infections, at 12.40% (USD 101.51 million), are the fastest-growing segment as guidelines recommend extra-genital testing for men who have sex with men and others at risk, and ocular and other infections, including pharyngeal and neonatal conjunctivitis, account for 6.40% (USD 52.39 million).

Chlamydia Infection Diagnostics Market by Setting 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Laboratory-based testing accounted for 74.60% (USD 610.68 million) in 2025 because clinics, physicians and screening programs send most samples to hospital and reference laboratories for high-throughput NAAT. Point-of-care and home testing, at 25.40% (USD 207.92 million), is the fastest-growing setting, supported by rapid molecular platforms in sexual health clinics and the first FDA-authorized over-the-counter home molecular test.

Chlamydia Infection Diagnostics Market by End User 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Diagnostic laboratories accounted for 40.60% (USD 332.35 million) in 2025, running large volumes of screening tests. Hospitals, at 34.20% (USD 279.96 million), test emergency, obstetric and inpatient patients; specialty and sexual health clinics account for 18.60% (USD 152.26 million) and increasingly use rapid tests to treat patients in one visit; and home users account for 6.60% (USD 54.03 million).

• Analyst View: Segment values were allocated by matching test volumes by setting and sample site to test types and prices. NAATs are widely preferred because they dominate laboratory testing and have higher costs compared to other methods. We expect point-of-care and home testing, rectal and extra-genital testing, and sexual health clinics to gain share.

Regional Analysis

Chlamydia Infection Diagnostics Market by Region 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

North America accounted for 42.60% (USD 348.72 million) in 2025, growing on more than a million reported chlamydia cases a year in the United States, annual screening recommendations for sexually active women under 25, broad NAAT capacity, and new at-home and point-of-care options. Europe, at 26.80% (USD 219.38 million), is supported by national chlamydia screening and sexual health services in the UK, the Nordic countries, Germany and the Netherlands, where online self-sampling is widely used. Asia Pacific, at 21.20% (USD 173.54 million), is the fastest-growing region, supported by rising STI awareness, expanding molecular testing in China, Japan, Australia and South Korea and growing private laboratory networks in India. Latin America, at 5.20% (USD 42.57 million), and the Middle East and Africa, at 4.20% (USD 34.38 million), are smaller markets where much testing still relies on syndromic management, but molecular testing is expanding in urban centers.

North America accounted for 42.60% (USD 348.72 million) in 2025. High reported case numbers and routine screening drive testing. Large reference laboratories run most NAATs. Home and point-of-care molecular tests add new channels.

Europe accounted for 26.80% (USD 219.38 million) in 2025. Sexual health services and online self-sampling support testing. The UK and Nordic countries have high testing rates. Laboratory NAAT is standard practice.

Asia Pacific accounted for 21.20% (USD 173.54 million) in 2025 and is the fastest-growing region. Molecular testing is expanding in China, Japan, and Australia. Private laboratories in India are adding STI panels. Awareness programs increase screening.

Latin America accounted for 5.20% (USD 42.57 million) in 2025. Brazil and Mexico are ahead in lab tests. Syndromic approach is prevalent.

The Middle East and Africa accounted for 4.20% (USD 34.38 million) in 2025. Testing access is limited in many countries. Donor programs support molecular STI testing in parts of Africa.

• Analyst View: Regional shares were built from test volumes, screening coverage, and test prices in each region. North America leads because of high screening rates and NAAT prices. We assign Asia Pacific the highest growth premium because molecular STI testing is expanding fastest there from a lower base.

Top 10 Companies in the Chlamydia Infection Diagnostics Market

Note: Company revenues and shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Hologic led the chlamydia infection diagnostics market with an estimated 22.23% (USD 182.00 million) of 2025 revenue, followed by Roche Diagnostics at 15.64% (USD 128.00 million) and BD at 8.80% (USD 72.00 million). Hologic leads with its Aptima Combo 2 chlamydia and gonorrhea assays run on automated Panther systems in many reference and public health laboratories. Roche and BD hold strong positions through cobas and BD molecular STI assays on high-throughput platforms, and Abbott competes with its Alinity m system. Cepheid leads rapid molecular testing in clinics and hospitals with Xpert CT/NG, while Visby Medical and binx health are bringing PCR testing to the point of care and the home. Seegene and bioMérieux offer multiplex STI panels that test for several infections at once. The leading 10 players held an estimated 73.78% (USD 604.00 million) of the market revenue in 2025, whereas the remaining 26.22% (USD 214.60 million) belonged to the regional manufacturers of molecular tests, rapid tests, and home collection services. The chlamydia infection diagnostics market is concentrated among a few molecular platform suppliers, and competition centers on sensitivity, sample types, automation, multiplex panels, and time to result. Point-of-care and at-home molecular tests are opening new channels, which is attracting newer companies alongside the established laboratory platform makers.

Recent Developments

• March 2025: The FDA granted marketing authorization to Visby Medical's Women's Sexual Health Test, the first over-the-counter at-home test for chlamydia, gonorrhea and trichomoniasis, with results in about 30 minutes.
• May 2025: Wisp launched its diagnostics portfolio of Common STI Panel for testing Chlamydia, Gonorrhea, and Trichomoniasis, a 3-Site Panel for testing Chlamydia and Gonorrhea, and an M-Gen Panel for testing Mycoplasma Genitalium.

Market Segments

By Test Type

• NAAT
• Serology & Rapid Tests
• Direct Fluorescent Antibody
• Culture

By Infection Type

• Genital
• Rectal
• Ocular & Others

By Setting

• Laboratory-based
• Point-of-Care & Home

By End User

• Diagnostic Laboratories
• Hospitals
• Specialty & Sexual Health Clinics
• Home Users

By Region

• North America (U.S., Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)
• Asia Pacific (China, Japan, India, South Korea, Taiwan, Rest of Asia Pacific)
• Latin America (Brazil, Argentina, Rest of Latin America)
• Middle East & Africa (GCC, South Africa, Rest of MEA)

Research Methodology

The chlamydia infection diagnostics market was defined as NAATs, direct fluorescent antibody tests, culture, serology, rapid tests, and collection kits used to diagnose Chlamydia trachomatis infection worldwide. The 2025 base year was built bottom-up from chlamydia test volumes by setting screening rates and test prices, and checked top-down against the STI testing revenue of leading molecular diagnostics companies. Segment, regional and company values were allocated from test types, infection types, settings, end users and regional testing. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.

Analyst View: Overall Market

The chlamydia infection diagnostics market is driven by routine screening with molecular tests, while rapid and home testing are adding new channels. Our estimate links demand to test volumes, settings, and test prices, so the forecast follows screening coverage, infection rates and adoption of decentralized testing. The greatest benefit would be through home testing kits and point-of-care molecular tests, while the greatest threats would include pricing and lack of testing in asymptomatic individuals.

Sources and References

1. US FDA. "FDA grants marketing authorization for first home test for chlamydia, gonorrhea and trichomoniasis". 2025-03-28. Visby Medical Women's Sexual Health Test. https://www.fda.gov/news-events/press-announcements/fda-grants-marketing-authorization-first-home-test-chlamydia-gonorrhea-and-trichomoniasis
2. Healthcare Purchasing News. "FDA grants marketing authorization to at-home chlamydia and gonorrhea test". 2025-03-28. At-home STI test. https://www.hpnonline.com/infection-prevention/news/55278168/fda-grants-marketing-authorization-to-at-home-chlamydia-and-gonorrhea-test
3. 360Dx. "FDA authorizes Visby Medical home MDx test for chlamydia, gonorrhea". 2025. Visby home test authorisation. https://www.360dx.com/regulatory-news-fda-approvals/fda-authorizes-visby-medical-home-mdx-test-chlamydia-gonorrhea